Abstract
There is an expanding body of literature regarding the utility of novel biomarkers in drug-induced kidney injury (DIKI) and other forms of acute kidney injury (AKI). The authors could not thoroughly review this topic without referring to and acknowledging this work. Included is a list of additional articles (see Supplementary Reading List) that have been referenced, but not cited within the body of the text. These references have provided data used within this article and have allowed the authors to discuss the epidemiology of DIKI, its classification, the utility of specific biomarkers, and the impact that comorbid illness and medications can have on their levels.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
